22.35 +0.05 (0.22%)
After hours: 7:59PM EST
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||22.18 - 22.86|
|52 Week Range||8.31 - 24.43|
|PE Ratio (TTM)||5.69|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
Valeant Pharmaceuticals International Inc (NYSE:VRX) is trading with a trailing P/E of 5.6x, which is lower than the industry average of 24.2x. Although some investors may jump to the conclusionRead More...
Generic-drug makers were hit Thursday after hospitals said they would make medicines themselves to circumvent high prices.
RBC Capital analysts argue Allergan could raise around $1 billion and send a "strong signal" on profitability with the sale of its anti-infectives business.
Showering its investors with good news, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is trading close to its yearly highs. Since early November, VRX stock has more than doubled, and for good reason. The company extended the maturities of its upcoming debt obligations.
Bill Ackman’s $290 million settlement agreement with shareholders of drug developer Allergan plc has the support of a California federal judge. This is good news for the New York-based activist investor and Valeant Pharmaceuticals, as the two parties are being sued for insider trading. “The Court has vacated the trial date and indicated its preliminary approval of the settlement subject to submission of final papers and associated hearings,” Valeant said in a statement.
A federal judge signaled he would approve a $290 million settlement reached by Pershing Square, Valeant and the shareholders of Allergan who had alleged the two firms improperly profited from their failed ...
It’s exceedingly difficult to find something to dislike about UnitedHealth Group Inc (NYSE:UNH) stock. In a healthcare sector filled with minefields over the past few years, UnitedHealth stock has tripled over the past four years. Valuation might seem a slight concern, but UNH stock isn’t that expensive on an earnings basis, nor is its balance sheet particularly levered.
Shares of Valeant Pharmaceuticals International (VRX) have more than doubled the S&P 500's return during the past 12 months. H.C. Wainwright's Raghuram Selvaraju is warming to the stock. Valeant has made "significant strides" in moving its pipeline forward in recent months, he writes, while also making "substantial progress" on its debt.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? In December 2017, Teva Pharmaceutical Industries (TEVA) laid out a detailed restructuring plan for the company to turn around its ailing business due to a number of challenges it’s facing.
Shares of Valeant Pharmaceuticals International (VRX) are higher on Friday, following acceptance of the application of one of its subsidiaries' acne medications. Valeant said that the Food and Drug Administration approved its New Drug Application for its tretinoin acne lotion, with an approval date of August 27, 2018.
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form
PDUFA Date Is Aug. 27, 2018 LAVAL, Quebec , Jan. 12, 2018 /PRNewswire/ -- Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") , ...
Pershing Square Holdings, the hedge fund operated by noted activist investor Bill Ackman, on Wednesday announced it was slashing its management fees, a move related to the settlement of two class-action ...
Activist investor Bill Ackman said he would slash the 1.5 percent annual management fee for his hedge fund Pershing Square Holdings Ltd. According to a letter posted to the Pershing Square (PSHZF) website, Ackman says he will be reducing future management fees for all of the funds which incurred recent litigation expenses by a total of $32.2 million. The litigation referenced in the letter pertains to Ackman and Valeant Pharmaceuticals' settling a long-standing dispute against drug developer Allergan plc.
Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has been on a tear in recent months, nearly doubling since November 1, when it closed at $11.93 a share. Valeant announced its results on November 7, with the news it beat analyst estimates for both revenue and net income. The company has also made progress in reducing its substantial debt burden.
NEW YORK, NY / ACCESSWIRE / January 11, 2018 / All three major indexes dropped Wednesday on news that China is considering halting the purchases of U.S. sovereign debt, with the S&P 500 and Nasdaq logging ...
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has begun a turnaround. The Laval, Canada-based drug manufacturer is on a growth path again after VRX stock came crashing from lofty highs. A new CEO now works to drive profits and reduce a heavy debt burden.
Valeant Pharmaceuticals International Inc. became a household name with its historic rise and fall. Reviving the drugmaker is proving a unique challenge.
With the stock of the drugmaker hovering around $23 a share and its reputation bloodied, CEO Joe Papa tried to explain his company's comeback efforts to investors.
At its heart, the bull/bear battle over Shopify Inc (US) (NYSE:SHOP) stock is an argument over valuation. Over the past six months, that battle mostly has been a stalemate, with SHOP stock up modestly from early August, when it first cleared $100. Most notably, SHOP stock tanked after short-seller Citron Research took aim at the stock back in October.
Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest in the markets.
At the J.P. Morgan Health Care Conference, Valeant CEO Joe Papa speaks with CNBC's Meg Tirrell about the turnaround in the company and their drug pricing strategy.